MA53164A - Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase - Google Patents
Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinaseInfo
- Publication number
- MA53164A MA53164A MA053164A MA53164A MA53164A MA 53164 A MA53164 A MA 53164A MA 053164 A MA053164 A MA 053164A MA 53164 A MA53164 A MA 53164A MA 53164 A MA53164 A MA 53164A
- Authority
- MA
- Morocco
- Prior art keywords
- rho
- kinase inhibitors
- amide derivatives
- derivatives used
- tyrosine amide
- Prior art date
Links
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical class NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 title 1
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18183733 | 2018-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53164A true MA53164A (fr) | 2021-05-26 |
Family
ID=62975943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053164A MA53164A (fr) | 2018-07-16 | 2019-07-12 | Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210284639A1 (fr) |
EP (1) | EP3823969A1 (fr) |
JP (1) | JP2021529819A (fr) |
KR (1) | KR20210032977A (fr) |
CN (1) | CN112752757B (fr) |
AR (1) | AR115766A1 (fr) |
AU (1) | AU2019304472A1 (fr) |
BR (1) | BR112021000101A2 (fr) |
CA (1) | CA3104955A1 (fr) |
MA (1) | MA53164A (fr) |
MX (1) | MX2021000270A (fr) |
TW (1) | TW202019923A (fr) |
WO (1) | WO2020016129A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023005865A (es) | 2020-12-15 | 2023-06-05 | Chiesi Farm Spa | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. |
EP4263548A1 (fr) | 2020-12-15 | 2023-10-25 | Chiesi Farmaceutici S.p.A. | Dérivés de dihydrofuropyridine en tant qu'inhibiteurs de la rho-kinase |
AU2021402528A1 (en) | 2020-12-15 | 2023-07-27 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2023110700A1 (fr) | 2021-12-13 | 2023-06-22 | Chiesi Farmaceutici S.P.A. | Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho-kinase |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1562935B1 (fr) | 2002-10-28 | 2006-09-06 | Bayer HealthCare AG | Phenylaminopyrimidine substituee par heteroaryloxy et utilisee en tant qu'inhibiteur de kinase |
US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
EP1756092A4 (fr) | 2004-06-17 | 2009-12-02 | Smithkline Beecham Corp | Inhibiteurs novateurs de protéines rho-kinases |
WO2007026920A2 (fr) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Nouveaux composes |
EP2234618A4 (fr) | 2007-12-21 | 2011-04-27 | Scripps Research Inst | Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase |
EP2100598A1 (fr) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
MX2011002825A (es) | 2008-09-18 | 2011-04-05 | Astellas Pharma Inc | Compuestos heterociclicos de carboxamida. |
SG186989A1 (en) | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
CA2838777C (fr) * | 2011-06-10 | 2019-04-30 | Chiesi Farmaceutici S.P.A. | Composes ayant une activite antagoniste des recepteurs muscariniques et une activite agoniste des recepteurs adrenergique beta-2 |
US9682963B2 (en) | 2013-01-29 | 2017-06-20 | Redx Pharma Plc | Pyridine derivatives as soft rock inhibitors |
AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
EA039783B1 (ru) * | 2017-01-30 | 2022-03-14 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ |
-
2019
- 2019-06-24 TW TW108121992A patent/TW202019923A/zh unknown
- 2019-07-11 AR ARP190101969A patent/AR115766A1/es unknown
- 2019-07-12 CA CA3104955A patent/CA3104955A1/fr active Pending
- 2019-07-12 KR KR1020217003030A patent/KR20210032977A/ko active Search and Examination
- 2019-07-12 WO PCT/EP2019/068832 patent/WO2020016129A1/fr unknown
- 2019-07-12 JP JP2021501323A patent/JP2021529819A/ja active Pending
- 2019-07-12 CN CN201980047406.6A patent/CN112752757B/zh active Active
- 2019-07-12 MA MA053164A patent/MA53164A/fr unknown
- 2019-07-12 EP EP19744641.2A patent/EP3823969A1/fr active Pending
- 2019-07-12 US US17/260,631 patent/US20210284639A1/en active Pending
- 2019-07-12 MX MX2021000270A patent/MX2021000270A/es unknown
- 2019-07-12 AU AU2019304472A patent/AU2019304472A1/en active Pending
- 2019-07-12 BR BR112021000101-8A patent/BR112021000101A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021000270A (es) | 2021-03-26 |
CA3104955A1 (fr) | 2020-01-23 |
KR20210032977A (ko) | 2021-03-25 |
CN112752757A (zh) | 2021-05-04 |
AR115766A1 (es) | 2021-02-24 |
BR112021000101A2 (pt) | 2021-03-30 |
TW202019923A (zh) | 2020-06-01 |
EP3823969A1 (fr) | 2021-05-26 |
AU2019304472A1 (en) | 2021-02-11 |
US20210284639A1 (en) | 2021-09-16 |
CN112752757B (zh) | 2024-01-12 |
JP2021529819A (ja) | 2021-11-04 |
WO2020016129A1 (fr) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA51610A (fr) | Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17 | |
MA54452A (fr) | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a | |
MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
MA53164A (fr) | Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase | |
MA51290A (fr) | Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1 | |
MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
MA49566A (fr) | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques | |
MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
MA54157A (fr) | Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1) | |
MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA48943A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase |